Clinical Trial Update: Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and effectiveness of an adjuvant to improve immune response to hepatitis B vaccine in HIV-infected individuals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED